115 related articles for article (PubMed ID: 26560487)
1. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Lee O; Ivancic D; Allu S; Shidfar A; Kenney K; Helenowski I; Sullivan ME; Muzzio M; Scholtens D; Chatterton RT; Bethke KP; Hansen NM; Khan SA
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1235-46. PubMed ID: 26560487
[TBL] [Abstract][Full Text] [Related]
2. Novel routes for administering chemoprevention: local transdermal therapy to the breasts.
Lee O; Khan SA
Semin Oncol; 2016 Feb; 43(1):107-115. PubMed ID: 26970129
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
[TBL] [Abstract][Full Text] [Related]
4. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Khan SA; Mi X; Xu Y; Blanco LZ; Akasha AM; Pilewskie M; Degnim AC; AlHilli Z; Amin AL; Hwang ES; Guenther JM; Kocherginsky M; Benante K; Zhang S; Helland T; Hustad SS; Gursel DB; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Lee O
JAMA Surg; 2023 Dec; 158(12):1265-1273. PubMed ID: 37870954
[TBL] [Abstract][Full Text] [Related]
5. Review: Patient-controlled transdermal 4-hydroxytamoxifen (4-OHT) vs. oral tamoxifen: A systematic review and meta analysis.
Sundralingam U; Khan TM; Elendran S; Muniyandy S; Palanisamy UD
Pak J Pharm Sci; 2019 May; 32(3):1121-1128. PubMed ID: 31278729
[TBL] [Abstract][Full Text] [Related]
6. Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double-Blind, Placebo-Controlled Phase II Trial.
Lee O; Pilewskie M; Karlan S; Tull MB; Benante K; Xu Y; Blanco L; Helenowski I; Kocherginsky M; Yadav S; Hosseini O; Hansen N; Bethke K; Muzzio M; Troester MA; Dimond E; Perloff M; Heckman-Stoddard B; Khan SA
Clin Pharmacol Ther; 2021 Mar; 109(3):728-738. PubMed ID: 32996592
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
8. A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects.
Lee O; Bazzi LA; Xu Y; Pearson E; Wang M; Hosseini O; Akasha AM; Choi JN; Karlan S; Pilewskie M; Kocherginsky M; Benante K; Helland T; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Khan SA
Biomed Pharmacother; 2024 Feb; 171():116105. PubMed ID: 38171245
[TBL] [Abstract][Full Text] [Related]
9. Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.
Karavites LC; Allu S; Khan SA; Kaiser K
BMC Cancer; 2015 Nov; 15():878. PubMed ID: 26552376
[TBL] [Abstract][Full Text] [Related]
10. Novel iontophoretic administration method for local therapy of breast cancer.
Komuro M; Suzuki K; Kanebako M; Kawahara T; Otoi T; Kitazato K; Inagi T; Makino K; Toi M; Terada H
J Control Release; 2013 Jun; 168(3):298-306. PubMed ID: 23562634
[TBL] [Abstract][Full Text] [Related]
11. Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats.
Sauvez F; Drouin DS; Attia M; Bertheux H; Forster R
Carcinogenesis; 1999 May; 20(5):843-50. PubMed ID: 10334202
[TBL] [Abstract][Full Text] [Related]
12. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
13. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems.
Sintov AC; Botner S
Int J Pharm; 2006 Mar; 311(1-2):55-62. PubMed ID: 16431047
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of Breast Cancer by Transdermal Delivery of α-Santalol through Breast Skin and Mammary Papilla (Nipple).
Dave K; Alsharif FM; Islam S; Dwivedi C; Perumal O
Pharm Res; 2017 Sep; 34(9):1897-1907. PubMed ID: 28589445
[TBL] [Abstract][Full Text] [Related]
15. In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast.
Lee O; Ivancic D; Chatterton RT; Rademaker AW; Khan SA
Breast Cancer (Dove Med Press); 2011; 3():61-70. PubMed ID: 24367176
[TBL] [Abstract][Full Text] [Related]
16. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
[TBL] [Abstract][Full Text] [Related]
17. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.
Zhong Q; Zhang C; Zhang Q; Miele L; Zheng S; Wang G
BMC Cancer; 2015 Sep; 15():625. PubMed ID: 26354796
[TBL] [Abstract][Full Text] [Related]
18. Ductal access for prevention and therapy of mammary tumors.
Murata S; Kominsky SL; Vali M; Zhang Z; Garrett-Mayer E; Korz D; Huso D; Baker SD; Barber J; Jaffee E; Reilly RT; Sukumar S
Cancer Res; 2006 Jan; 66(2):638-45. PubMed ID: 16423990
[TBL] [Abstract][Full Text] [Related]
19. A novel nano-carrier transdermal gel against inflammation.
Chaudhary H; Kohli K; Kumar V
Int J Pharm; 2014 Apr; 465(1-2):175-86. PubMed ID: 24548719
[TBL] [Abstract][Full Text] [Related]
20. Microemulsion and poloxamer microemulsion-based gel for sustained transdermal delivery of diclofenac epolamine using in-skin drug depot: in vitro/in vivo evaluation.
Fouad SA; Basalious EB; El-Nabarawi MA; Tayel SA
Int J Pharm; 2013 Sep; 453(2):569-78. PubMed ID: 23792042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
